Ionis Pharmaceuticals
IONS
314 hedge funds and large institutions have $4.28B invested in Ionis Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 103 increasing their positions, 109 reducing their positions, and 72 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 109
11% less funds holding
Funds holding: 353 → 314 (-39)
25% less capital invested
Capital invested by funds: $5.72B → $4.28B (-$1.44B)
28% less call options, than puts
Call options by funds: $50.3M | Put options by funds: $70.2M
53% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 72
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$409M |
| 2 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$36.5M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$24.5M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$22.4M |
| 5 |
Renaissance Technologies
New York
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$39.9M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$29M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$24.3M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$22.3M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$20.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
376
Twin Tree Management
Dallas,
Texas
| – | -$38K | -652 | Closed |
|
|
HCMT
377
Highland Capital Management (Tennessee)
Memphis,
Tennessee
| – | -$29K | -500 | Closed |
|
|
BRWM
378
B. Riley Wealth Management
Memphis,
Tennessee
| – | -$21K | -373 | Closed |
|
|
CLOS
379
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$17K | -300 | Closed |
|
|
FMII
380
Farmers & Merchants Investments Inc
Lincoln,
Nebraska
| – | -$17K | -300 | Closed |
|
|
CHP
381
Cable Hill Partners
Portland,
Oregon
| – | -$7K | -113 | Closed |
|
|
FANJ
382
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$5K | -80 | Closed |
|
|
MA
383
MUFG Americas
New York
| – | -$4K | -75 | Closed |
|
|
VIA
384
Vantage Investment Advisors
State College,
Pennsylvania
| – | -$3K | -50 | Closed |
|
|
RCG
385
Ruggie Capital Group
Tavares,
Florida
| – | -$1K | -20 | Closed |
|
|
W
386
Wealthfront
Palo Alto,
California
| – | +$155 | +3 | New |
|
IONS Hedge Fund Activity: Q3 2015 in Review
314 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2015, worth a combined $4.28B — down 25% from $5.72B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of IONS and 34 opened new positions — a net loss of 38 holders — while 109 trimmed existing stakes and 103 added.
The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $409M. The largest seller was Northern Trust, cutting an estimated $39.9M.
- 314 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2015, down from 353 in Q2 2015.
- Funds reported $4.28B of Ionis Pharmaceuticals stock for Q3 2015, down 25% quarter-over-quarter.
- 34 funds opened new Ionis Pharmaceuticals positions in Q3 2015 and 72 closed out, a net change of -38 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2015 was Baillie Gifford & Co, an estimated $409M added.
- The largest Ionis Pharmaceuticals seller in Q3 2015 was Northern Trust, an estimated $39.9M sold.
Based on aggregated 13F filings for Q3 2015.